A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-05-10
Adverse events
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-30 (study day 11); relationship: Y; serious criteria: hospitalization
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-14 (study day 26); relationship: Y
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-08-05 (study day 78); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-25 (study day 159); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-10-26 (study day 160); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-21 (study day 186); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-29 (study day 255); relationship: N
Data queries
No data queries.